Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment

1. Christofides, E.A.
2. Stankiewicz, A.
3. Denham, D.
4. Bellido, D.
5. Franek, E.
6. Nakhle, S.
7. Łukaszewicz, M.
8. Reed, J.
9. Cózar-León, V.
10. Kosch, C.
11. Karaś, P.
12. Fitz-Patrick, D.
13. Handelsman, Y.
14. Warren, M.
15. Hollander, P.
16. Huffman, D.
17. Raskin, P.
18. Oroszlán, T.
19. Lillestol, M.
20. Ovalle, F.